NCT02512302View on ClinicalTrials.gov

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
COPD
Interventions
DRUG

SUN-101 via eFlow nebulizer

50 mcg glycopyrrolate via Electronic Nebulizer

DRUG

SUN-101 via eFlow nebulizer with activated charcoal

50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

DRUG

Seebri® Breezhaler®

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

DRUG

Seebri® Breezhaler® with activated charcoal

63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

DRUG

Glycopyrrolate Injection

50 mcg glycopyrrolate via IV

Trial Locations (2)

W1G 8HU

Queen Anne Street Medical Center, London

M23 9QZ

Medicines evaluation Unit Ltd., Manchester

All Listed Sponsors
lead

Sunovion Respiratory Development Inc.

INDUSTRY

NCT02512302 - Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). | Biotech Hunter | Biotech Hunter